Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 5/20 | 0.44 |
| ▸ | MTOR | P42345 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | IDH2 | P48735 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15615876 | 0.84 | MPO (0.51) | CTSCMTORTP53MAPTSMN1; SMN2 | |
| SCHEMBL28821019 | 0.83 | CTSC (0.45) | CTSCMTORTP53MAPTSMN1; SMN2 | |
| SCHEMBL16804753 | 0.83 | MTOR (0.43) | CTSCMTORTP53MAPTSMN1; SMN2 | |
| SCHEMBL27930761 | 0.82 | MTOR (0.39) | CTSCMTORTP53MAPTSMN1; SMN2 | |
| SCHEMBL15615888 | 0.81 | LMNA (0.53) | MTORTP53MAPTIDH2POLB | |
| SCHEMBL16086165 | 0.81 | IDH2 (0.44) | CTSCMTORTP53MAPTSMN1; SMN2 | |
| SCHEMBL15615882 | 0.78 | MAPT (0.52) | TP53MAPTSMN1; SMN2AURKAALDH1A1 | |
| SCHEMBL20430476 | 0.78 | MELK (0.40) | MTORTRPV1EGFRERBB2 | |
| SCHEMBL15615969 | 0.73 | CNR2 (0.58) | POLBAPP | |
| SCHEMBL14978583 | 0.72 | MTOR (0.44) | MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2719697-B1 | PYRIDONAPHTHYRIDINE PI3K/MTOR DUAL INHIBITORS AND PREPARATION AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2018-08-01 | — | — | EP | disclosed |
| EP-2719697-B1 | PYRIDONAPHTHYRIDINE PI3K/MTOR DUAL INHIBITORS AND PREPARATION AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2018-08-01 | — | — | EP | disclosed |
| US-9475812-B2 | Pyridonaphthyridine type dual PI3K and mTOR inhibitor and its preparation and use | Xuanzhu Pharma Co., Ltd. (CN) | 2016-10-25 | — | — | US | disclosed |
| US-9475812-B2 | Pyridonaphthyridine type dual PI3K and mTOR inhibitor and its preparation and use | Xuanzhu Pharma Co., Ltd. (CN) | 2016-10-25 | — | — | US | disclosed |
| US-9475812-B2 | Pyridonaphthyridine type dual PI3K and mTOR inhibitor and its preparation and use | Xuanzhu Pharma Co., Ltd. (CN) | 2016-10-25 | — | — | US | disclosed |
| EP-2781520-B1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | XUANZHU PHARMA CO LTD (CN) | 2016-05-04 | — | — | EP | disclosed |
| US-9284315-B2 | Three-ring PI3K and/or mTOR inhibitor | ZUANZHU PHARMA CO., LTD. (CN) | 2016-03-15 | — | — | US | disclosed |
| US-9284315-B2 | Three-ring PI3K and/or mTOR inhibitor | ZUANZHU PHARMA CO., LTD. (CN) | 2016-03-15 | — | — | US | disclosed |
| US-9284315-B2 | Three-ring PI3K and/or mTOR inhibitor | ZUANZHU PHARMA CO., LTD. (CN) | 2016-03-15 | — | — | US | disclosed |
| US-20150166539-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150166539-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150166539-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-18 | — | — | US | disclosed |
| EP-2781520-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| EP-2719697-A1 | PYRIDONAPHTHYRIDINE PI3K/MTOR DUAL INHIBITORS AND PREPARATION AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-04-16 | — | — | EP | disclosed |
| CN-103224496-A | Tricyclic PI3K and/or mTOR inhibitors | KBP BIOSCIENCES CO LTD | 2013-07-31 | — | — | CN | disclosed |
| WO-2013071698-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | 山东轩竹医药科技有限公司 (CN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166539-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | MTOR, RICTOR, AKT3 | CTSC 3439/4885MTOR 1/4885TP53 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.